Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) saw a significant growth in short interest in September. As of September 15th, there was short interest totaling 184,114 shares, a growth of 56.8% from the August 31st total of 117,438 shares. Based on an average daily volume of 4,206 shares, the short-interest ratio is currently 43.8 days. Approximately 0.2% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised shares of Oxford BioMedica to a “hold” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Oxford BioMedica currently has a consensus rating of “Hold”.
Check Out Our Latest Analysis on Oxford BioMedica
Oxford BioMedica Price Performance
Oxford BioMedica Company Profile
Oxford BioMedica plc is a United Kingdom-based contract development and manufacturing organization (CDMO) focused on cell and gene therapies. The company helps biotechnology and pharmaceutical customers develop, test, and manufacture advanced therapies, with expertise in viral-vector technologies used to deliver genetic material into cells.
Its services include process and analytical development, clinical and commercial manufacturing, quality testing, regulatory support, and related research services.
See Also
- Five stocks we like better than Oxford BioMedica
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
- 3 Emerging Biotech Stocks With Significant Upside Potential
- Treasury Yields Haven’t Been This High Since 2007—3 ETFs to Watch
- 3 Healthcare Dividend Stocks Offering More Than Just Income
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
